HC Wainwright Issues Pessimistic Outlook for TNGX Earnings

Key Points

• HC Wainwright cut its Tango Therapeutics Q3 2026 EPS estimate to a loss of $0.32 from $0.26 and now expects a $1.34-per-share loss for full-year 2026, signaling higher anticipated losses.
• Despite the reduced earnings outlook, HC Wainwright maintained a Buy rating and $68 price target. Analysts overall remain bullish, with 13 Buy ratings, two Holds, one Sell, and an average target of $43.46.
• Tango shares opened at $25.20 and were down 0.9%, while the company reported a recent quarterly loss of $0.37 per share that missed consensus by $0.05. Institutional investors own nearly 79% of the stock, and an insider recently sold 27,000 shares.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Stock analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of Tango Therapeutics in a research note issued to investors on Tuesday, August 18th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.32) for the quarter, down from their prior forecast of ($0.26). HC Wainwright has a "Buy" rating and a $68.00 price objective on the stock. The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for Tango Therapeutics' Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.34) EPS and Q1 2027 earnings at ($0.35) EPS.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.05).

A number of other research analysts have also recently issued reports on TNGX. Stifel Nicolaus lifted their price objective on shares of Tango Therapeutics from $24.00 to $40.00 and gave the company a "buy" rating in a research note on Monday, April 27th. Weiss Ratings raised Tango Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Wedbush upped their price objective on Tango Therapeutics from $19.00 to $33.00 and gave the stock an "outperform" rating in a research report on Thursday, May 14th. Canaccord Genuity Group raised their price objective on Tango Therapeutics from $42.00 to $46.00 and gave the company a "buy" rating in a research note on Monday, June 29th. Finally, Guggenheim lifted their target price on Tango Therapeutics from $32.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $43.46.

Tango Therapeutics Trading Down 0.9%

Shares of NASDAQ:TNGX opened at $25.20 on Thursday. The firm has a 50 day moving average of $28.62 and a 200-day moving average of $22.61. The stock has a market capitalization of $4.25 billion, a PE ratio of -29.65 and a beta of 1.16. Tango Therapeutics has a 12 month low of $6.25 and a 12 month high of $34.39.

Insiders Place Their Bets

In related news, insider Adam Crystal sold 27,000 shares of the firm's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total transaction of $798,930.00. Following the completion of the transaction, the insider directly owned 115,743 shares of the company's stock, valued at $3,424,835.37. This trade represents a 18.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 6.50% of the stock is owned by insiders.

Institutional Trading of Tango Therapeutics

Several institutional investors have recently added to or reduced their stakes in TNGX. BlackRock Inc. acquired a new stake in shares of Tango Therapeutics during the second quarter worth $388,826,000. Adage Capital Partners GP L.L.C. raised its position in shares of Tango Therapeutics by 322.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company's stock worth $93,986,000 after acquiring an additional 8,096,924 shares in the last quarter. TRV GP IV LLC acquired a new position in shares of Tango Therapeutics in the 2nd quarter valued at about $120,181,383,000. Jupiter Topco LLC acquired a new position in shares of Tango Therapeutics in the 2nd quarter valued at about $157,989,000. Finally, Caligan Partners LP bought a new stake in shares of Tango Therapeutics during the 4th quarter valued at about $33,047,000. 78.99% of the stock is currently owned by institutional investors.

Key Headlines Impacting Tango Therapeutics

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target for TNGX to $68 from $66 and reiterated a Buy rating. The new target implies substantial upside from the referenced $25.20 share price, providing a positive valuation signal for investors. HC Wainwright Increases Tango Therapeutics Price Target to $68
• Positive Sentiment: The analyst’s long-term outlook remains constructive, with projected 2027 quarterly losses of $0.37 to $0.41 per share and a full-year loss estimate of $1.54 per share, while maintaining the Buy rating and $68 target.
• Neutral Sentiment: HC Wainwright expects Tango Therapeutics to remain unprofitable through 2026 and 2027, forecasting fiscal 2026 EPS of negative $1.34 and fiscal 2027 EPS of negative $1.54. These estimates reinforce the company’s development-stage profile and suggest that investor sentiment will remain tied to clinical and pipeline progress rather than current earnings.
• Negative Sentiment: HC Wainwright reduced its fiscal 2026 EPS forecast to negative $1.34 from negative $1.15. It also cut its third-quarter estimate to negative $0.32 from negative $0.26 and its fourth-quarter estimate to negative $0.34 from negative $0.27, indicating higher anticipated losses than previously expected.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source